176 related articles for article (PubMed ID: 28337337)
1. Drug trapping in hERG K
Linder T; Bernsteiner H; Saxena P; Bauer F; Erker T; Timin E; Hering S; Stary-Weinzinger A
Medchemcomm; 2016 Mar; 7(3):512-518. PubMed ID: 28337337
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into trapping and dissociation of small molecules in K⁺ channels.
Linder T; Saxena P; Timin E; Hering S; Stary-Weinzinger A
J Chem Inf Model; 2014 Nov; 54(11):3218-28. PubMed ID: 25297379
[TBL] [Abstract][Full Text] [Related]
3. Trapping and dissociation of propafenone derivatives in HERG channels.
Windisch A; Timin E; Schwarz T; Stork-Riedler D; Erker T; Ecker G; Hering S
Br J Pharmacol; 2011 Apr; 162(7):1542-52. PubMed ID: 21175572
[TBL] [Abstract][Full Text] [Related]
4. The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives.
Thai KM; Windisch A; Stork D; Weinzinger A; Schiesaro A; Guy RH; Timin EN; Hering S; Ecker GF
ChemMedChem; 2010 Mar; 5(3):436-42. PubMed ID: 20146282
[TBL] [Abstract][Full Text] [Related]
5. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.
Mitcheson JS; Chen J; Sanguinetti MC
J Gen Physiol; 2000 Mar; 115(3):229-40. PubMed ID: 10694252
[TBL] [Abstract][Full Text] [Related]
6. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.
De Bruin ML; Pettersson M; Meyboom RH; Hoes AW; Leufkens HG
Eur Heart J; 2005 Mar; 26(6):590-7. PubMed ID: 15637086
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants for high-affinity block of hERG potassium channels.
Mitcheson J; Perry M; Stansfeld P; Sanguinetti MC; Witchel H; Hancox J
Novartis Found Symp; 2005; 266():136-50; discussion 150-8. PubMed ID: 16050266
[TBL] [Abstract][Full Text] [Related]
8. Antiviral and anti-inflammatory drugs to combat COVID-19: Effects on cardiac ion channels and risk of ventricular arrhythmias.
Cubeddu LX; de la Rosa D; Ameruoso M
Bioimpacts; 2022; 12(1):9-20. PubMed ID: 35087712
[No Abstract] [Full Text] [Related]
9. State dependent dissociation of HERG channel inhibitors.
Stork D; Timin EN; Berjukow S; Huber C; Hohaus A; Auer M; Hering S
Br J Pharmacol; 2007 Aug; 151(8):1368-76. PubMed ID: 17592502
[TBL] [Abstract][Full Text] [Related]
10. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
DI Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
J Cardiovasc Electrophysiol; 2014 Feb; 25(2):197-207. PubMed ID: 24118558
[TBL] [Abstract][Full Text] [Related]
11. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
12. Potent Inhibition of hERG Channels by the Over-the-Counter Antidiarrheal Agent Loperamide.
Klein MG; Haigney MCP; Mehler PS; Fatima N; Flagg TP; Krantz MJ
JACC Clin Electrophysiol; 2016 Dec; 2(7):784-789. PubMed ID: 29759761
[TBL] [Abstract][Full Text] [Related]
13. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
14. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
15. Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia.
Wan H; Selvaggio G; Pearlstein RA
PLoS One; 2020; 15(11):e0234946. PubMed ID: 33147278
[TBL] [Abstract][Full Text] [Related]
16. Rutaecarpine targets hERG channels and participates in regulating electrophysiological properties leading to ventricular arrhythmia.
Zhan G; Wang F; Ding YQ; Li XH; Li YX; Zhao ZR; Li JX; Liu Y; Zhao X; Yan CC; Li BX
J Cell Mol Med; 2021 Jun; 25(11):4938-4949. PubMed ID: 33939251
[TBL] [Abstract][Full Text] [Related]
17. The antipsychotic drug chlorpromazine inhibits HERG potassium channels.
Thomas D; Wu K; Kathöfer S; Katus HA; Schoels W; Kiehn J; Karle CA
Br J Pharmacol; 2003 Jun; 139(3):567-74. PubMed ID: 12788816
[TBL] [Abstract][Full Text] [Related]
18. Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.
Pareja K; Chu E; Dodyk K; Richter K; Miller A
Channels (Austin); 2013 Jan; 7(1):23-33. PubMed ID: 23221912
[TBL] [Abstract][Full Text] [Related]
19. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
[TBL] [Abstract][Full Text] [Related]
20. Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity.
Sheng J; Tran PN; Li Z; Dutta S; Chang K; Colatsky T; Wu WW
J Pharmacol Toxicol Methods; 2017; 88(Pt 2):109-122. PubMed ID: 28830713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
